WHO soft‑tissue FNA guidance article

A soft tissue lump can be anything from a harmless fatty growth to a sarcoma, and doctors often want an answer before they cut. Fine-needle aspiration is one way to get that answer: a thin needle pulls out cells, like sampling soup with a straw instead of removing the whole pot. (acsjournals.onlinelibrary.wiley.com) That quick needle test has a long-standing problem in soft tissue tumors: two pathologists can look at the same cells and describe them in different ways. A 2025 review said interobserver variability before standardization ran around 20% to 30%, which is a big gap when the next step could be surgery, molecular testing, or watchful waiting. (xiahepublishing.com) The World Health Organization built a reporting system to fix that language problem. The system was developed through the International Academy of Cytology, the International Agency for Research on Cancer, and the World Health Organization so cytology reports use the same categories across hospitals and countries. (publications.iarc.who.int) The basic idea is the same one airports use for security lines: sort people into clear lanes before deciding what happens next. The soft tissue system uses six lanes: nondiagnostic, benign, atypical, soft tissue neoplasm of uncertain malignant potential, suspicious for malignancy, and malignant. (xiahepublishing.com) Each lane comes with a risk of malignancy, which is a plain-language estimate of how often that category turns out to be cancer on follow-up. In a 2,214-case study from Institut Curie, the malignant category had a 97.69% risk of malignancy, while the benign category was 2.49%. (acsjournals.onlinelibrary.wiley.com) The middle categories are where this gets useful. In that same study, “atypical” carried a 39.62% risk of malignancy, “soft tissue neoplasm of uncertain malignant potential” was 51.43%, and “suspicious for malignancy” was 68.42%, which gives clinicians a more precise signal than a vague note saying “abnormal cells present.” (acsjournals.onlinelibrary.wiley.com) The article being highlighted now is a practical guide to using that system in real cases, not just a rulebook on a shelf. It reviews how to combine cell shape, clinical context, and extra lab tests so the report does more than label a sample. (xiahepublishing.com) Those extra lab tests matter because many soft tissue tumors look alike under a microscope. The World Health Organization framework specifically ties reporting to ancillary studies such as immunocytochemistry and molecular testing, which can separate look-alike tumors and help decide whether a patient needs excision, referral, or another biopsy. (publications.iarc.who.int) The evidence behind the system is better than a style guide with no scorecard. In the Institut Curie series, fine-needle aspiration for soft tissue tumors showed 98.3% sensitivity, 92.1% specificity, and 94.2% overall diagnostic accuracy, with 21 false negatives and 29 false positives. (acsjournals.onlinelibrary.wiley.com) The catch is that not all soft tissue tumors behave the same inside a category. The same study found the risk of malignancy also shifts by pattern, from 3.00% in lipomatous tumors to 100% in round cell tumors, which is why the guidance pushes pathologists to pair the category with the tumor’s morphologic pattern instead of stopping at a single label. (acsjournals.onlinelibrary.wiley.com) That is why a free-access explainer matters here. A standardized report turns “this looks worrisome” into a shared vocabulary with a risk estimate and a management path, which is exactly the kind of thing that makes cytology, surgical pathology, radiology, and oncology talk to each other without losing information in translation. (acsjournals.onlinelibrary.wiley.com)